Valuation: Omeros Corporation

Market Cap 139.49Cr 119.44Cr 111.74Cr 102.24Cr 192.39Cr 13TCr 194.58Cr 1.32TCr 514.25Cr 6.7TCr 523.72Cr 512.31Cr 22TCr P/E 2026 *
21.7x
P/E 2027 * 19.3x
Enterprise Value 139.49Cr 119.44Cr 111.74Cr 102.24Cr 192.39Cr 13TCr 194.58Cr 1.32TCr 514.25Cr 6.7TCr 523.72Cr 512.31Cr 22TCr EV / Sales 2026 *
11.1x
EV / Sales 2027 * 7.05x
Free-Float
95.92%
Yield 2026 *
-
Yield 2027 * -
1 day+3.44%
1 week+12.10%
Current month+62.75%
1 month+95.83%
3 months+68.15%
6 months+60.05%
Current year+12.20%
1 week 16.9
Extreme 16.9
19.58
1 month 9.77
Extreme 9.77
19.58
Current year 6.7
Extreme 6.7023
19.58
1 year 3.94
Extreme 3.94
19.58
3 years 0.92
Extreme 0.92
19.58
5 years 0.92
Extreme 0.92
19.58
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 16/06/1994
Director of Finance/CFO 62 30/06/2024
Chief Tech/Sci/R&D Officer 70 01/11/2019
Director TitleAgeSince
Chairman 67 16/06/1994
Director/Board Member 86 01/01/1995
Director/Board Member 72 01/01/1995
Date Insider Type Main position Quantity % Market Cap.
13/08/26 Fiscal year

Chief Financial Officer

15,000 0.0207%
12/08/26 Other

Director

5,28,082 0.7296%
12/08/26 Free

Director

30,000 0.0415%
Change 5-day change 1-year change 3-year change Capi.($)
+3.44%+12.10%+337.95%+419.41% 139.49Cr
-3.00%+2.27%+73.26%+109.90% 7.21TCr
+1.90%+23.53%+59.48%+94.82% 6.59TCr
+5.12%+25.22%+5.13%-5.86% 2.93TCr
+0.55%+1.64%-4.63%+480.92% 2.75TCr
+2.74%+12.98%+54.92%+25.77% 2.67TCr
+0.47%+6.12%+37.01%-15.31% 2.01TCr
+1.82%-6.67%+251.36%+388.91% 1.82TCr
+0.94%+3.36%+15.30%+548.19% 1.64TCr
+0.73%+5.54%+39.99%+151.77% 1.34TCr
Average +1.47%+8.74%+86.98%+219.85% 2.91TCr
Weighted average by Cap. +0.75%+9.49%+59.37%+159.11%

Financials

2026 *2027 *
Net sales 13Cr 11Cr 10Cr 9.21Cr 17Cr 1.2TCr 18Cr 118.83Cr 46Cr 603.39Cr 47Cr 46Cr 2TCr 20Cr 17Cr 16Cr 14Cr 27Cr 1.89TCr 28Cr 187.13Cr 73Cr 950.24Cr 74Cr 73Cr 3.14TCr
Net income 6.33Cr 5.42Cr 5.07Cr 4.64Cr 8.73Cr 605.65Cr 8.83Cr 60Cr 23Cr 304.1Cr 24Cr 23Cr 1.01TCr 7.95Cr 6.8Cr 6.37Cr 5.82Cr 11Cr 760.34Cr 11Cr 75Cr 29Cr 381.76Cr 30Cr 29Cr 1.26TCr
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
21/26/21 $19.27 +3.44% 25,82,621
20/26/20 $18.63 +1.31% 16,49,198
19/26/19 $18.39 +6.98% 31,97,709
18/26/18 $17.19 -0.98% 12,34,652
17/26/17 $17.36 +0.99% 24,67,443
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
19.27USD
Average target price
33.00USD
Spread / Average Target
+71.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock